About Mosanna

Barbara brings more than four decades of pharmaceutical industry experience to Mosanna, including over 30 years dedicated to regulatory affairs and quality assurance. She has built and led regulatory functions across both biotech and contract research organizations—guiding programs from early development through regulatory submission, review, and approval.

Barbara served as SVP of Regulatory Affairs and Quality Assurance at Otonomy, leading global regulatory strategy and serving as the primary interface with the FDA and other health authorities. She has also held leadership roles at Sonexa Therapeutics and Neurocrine Biosciences, contributing to the progression of multiple clinical-stage programs.

Kevin is a seasoned pharmaceutical development leader with over 20 years of experience advancing drug substance and drug product programs from early clinical stages through commercialization. He brings deep expertise in dry powder aerosol technology, analytical development, and manufacturing strategy.

Prior to joining Mosanna, Kevin served as VP of Pharmaceutical Development at Aerovate Therapeutics, leading all CMC activities and managing multiple CDMO partnerships to support global development programs. Previously as Executive Director of Analytical Development and Quality Control at Acorda Therapeutics, he transformed a start-up lab into a fully compliant FDA and EMA-approved commercial QC facility, contributing to the successful NDA and MAA approval of Inbrija^®.

David is a clinical development leader with over 35 years of experience leading global drug development across a wide range of therapeutic areas in biotechnology and CRO sectors. With a strong foundation in clinical operations, regulatory strategy, risk management, and quality systems, he has successfully guided products in CNS, oncology, endocrinology, and infectious diseases from early research to late-phase trials, securing regulatory approvals and shaping global development processes.

Before joining Mosanna, David held leadership positions at DTx Pharma, Otonomy Therapeutics, PAREXEL International, as well as Abide Therapeutics, Zavante Therapeutics, Sanofi-Aventis, Rhone-Poulenc Rorer, and Wyeth Ayerst. His contributions have been instrumental in the approval of several widely recognized therapies, including Venlafaxine^®, Rilutek^®, CombiPatch^®, Vivelle^®, Menorest^®, Arixtra^®, and Metadate ER^® / IR^®, shaping the pharmaceutical landscape globally.

Pranav is a finance and operations executive with a passion for building companies from the ground up. Over the past 15 years, he has helped launch and scale multiple venture-backed startups across biotech, healthcare, and agtech—often taking on cross-functional leadership roles during their earliest phases.

Most recently, Pranav was VP and Head of Finance at Sensorium Therapeutics, joining as the first employee and helping build the company’s finance, legal, IT, and operations functions from scratch. He worked closely with the CEO and Board to guide the company through multiple financings and support its growth from concept to clinic.

David is a biotechnology executive with over 30 years of experience leading drug development and corporate strategy across both public and private life sciences companies. He most recently served as President and CEO of Otonomy—guiding a successful IPO and the creation and advancement of multiple clinical-stage programs. Under his leadership, Otonomy achieved FDA approval of OTIPRIO^®, a single-dose antibiotic administered during ear tube surgery in children to help prevent infections.

As CEO of MacuSight, Inc., David advanced a sustained delivery formulation of sirolimus for severe ophthalmic diseases and secured a strategic licensing deal in Asia. He also served as CEO of Oculex Pharmaceuticals, which was acquired by Allergan, developing OZURDEX^®, for treatment of diabetic macular edema, macular edema associated with retinal vein occlusion, and noninfectious uveitis. He also held senior leadership roles at Oral-B Laboratories and Procter & Gamble—guiding new product development and clinical efforts across both medical and consumer health products.

Dr. White graduated from Emory University Medical School and completed training in Internal Medicine and Pulmonary Disease at the University of Colorado Health Sciences Center. He has held a number of positions at various universities over his career and is currently on the faculty at the Harvard Medical School. Some of his major accomplishments include being President of the American Academy of Sleep Medicine, Chairing the Task Force to write the research plan addressing sleep and its disorders for the National Institutes of Health, and being the Editor-in-Chief of the Journal SLEEP.

David was also on the test writing committees for the American Board of Internal Medicine for both Pulmonary Disease and Sleep Medicine and was the Chief Medical Officer for Respironics and subsequently Philips Respironics. Finally, his principal research interest has been the pathophysiology of disorders of breathing during sleep about which he has published over 290 original papers.

Ben has more than 25 years of experience in the biotech industry. He has been involved with the successful development of multiple drugs, including the first H1N1 vaccine available to the public in the United States. Most recently, Ben served as Chief Executive Officer of Vtesse, a company developing treatments for Niemann Pick Disease. After completion of its pivotal clinical study, the company was acquired in April 2017 by Sucampo Pharmaceuticals.

Prior to Vtesse, Ben served as COO of Omthera Pharmaceuticals, where he was responsible for the development and approval of a drug for the treatment of hypertriglyceridemia. He was integral in the IPO and subsequent acquisition of Omthera by AstraZeneca. Ben also served as EVP of Operations for MedImmune, spending 11 years there. In this role, he led the worldwide development and operations of MedImmune’s therapeutic antibodies, small molecules and vaccine products. He has held executive roles within product development, quality and operations at Xoma Corporation and Centocor BV. Currently chairman of the board of Polyneuron, Ben has served on the boards of Xencor, Tetragenetics, In, Comet Therapeutics and Complexa.